The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).
 
Patrick Schöffski
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Iteos Therapeutics; Mundipharma; Novartis; Pique; Plexxikon; Prime Oncology; SERVIER; Swedish Orphan Biovitrum; Threshold Pharmaceuticals; ThromboGenics
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Iteos Therapeutics; Mundipharma; Novartis; Pique; Plexxikon; SERVIER; Swedish Orphan Biovitrum; Threshold Pharmaceuticals; ThromboGenics
Speakers' Bureau - GlaxoSmithKline; Novartis; Prime Oncology; Swedish Orphan Biovitrum
 
Robert G. Maki
Stock and Other Ownership Interests - Agios; Celgene; Epizyme; Gilead Sciences; Karyopharm Therapeutics
Consulting or Advisory Role - Arcus Ventures; Bayer; Eisai; Gem Pharmaceuticals; GlaxoSmithKline; Lilly/ImClone; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma
Research Funding - Eisai (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Bayer/Onyx; Janssen Oncology
 
Antoine Italiano
Honoraria - GlaxoSmithKline; Pfizer; PharmaMar
Research Funding - Novartis; Pfizer; PharmaMar; Roche Pharma AG
 
Hans Gelderblom
No Relationships to Disclose
 
Giovanni Grignani
Honoraria - Bayer; Novartis; PharmaMar
 
Veridiana Pires De Camargo
No Relationships to Disclose
 
Sebastian Bauer
Honoraria - Sarcoma
Consulting or Advisory Role - Sarcoma
 
Sun Young Rha
No Relationships to Disclose
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pharmamar; PharmaMar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Novartis; PharmaMar; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst)
 
Peter Hohenberger
No Relationships to Disclose
 
David R. D'Adamo
Employment - Eisai
 
Benjamin Wang
Employment - Eisai
 
Bartosz Chmielowski
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Genentech (Inst); Lilly (Inst); Merck/Schering Plough (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Axel Le Cesne
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Novartis; Pfizer; PharmaMar
 
George D. Demetri
Consulting or Advisory Role - ARIAD; AstraZeneca; Bayer; BIND Therapeutics; Blueprint Medicines; Caris MPI; Champions Oncology; Daiichi Sankyo; EMD Serono; G1 Therapeutics; GlaxoSmithKline; Janssen Oncology; Kolltan Pharmaceuticals; Pfizer; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Bayer; EMD Serono; GlaxoSmithKline; Janssen Oncology; Novartis; Pfizer; Sanofi
 
Shreyaskumar Patel
Consulting or Advisory Role - CytRx Corporation; Janssen; Novartis
Research Funding - Eisai; Janssen; Morphotek